In the same study, a subgroup analysis of 14 EGFR mutated patients revealed that higher EGFR expression was associated with response to treatment and better PFS compared to non-responders, thereby indicating that serum EGFR mRNA expression may be a promising parameter for predicting therapeutic response in NSCLC, especially those who are EGFR mutated. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.